2. Academic Validation
  3. P2Y6 receptor: A promising therapeutic target for atherosclerosis

P2Y6 receptor: A promising therapeutic target for atherosclerosis

  • Eur J Pharmacol. 2025 Jul 5:998:177513. doi: 10.1016/j.ejphar.2025.177513.
Lixia Li 1,  Liting Lai 1,  Dan Qiu 1,  Yang Ding 1,  Meiling Yu 1,  Tingyu Zhang 1,  Zongbao Wang 2,  Shuzhi Wang 3
Affiliations

Affiliations

  • 1 School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
  • 2 School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Electronic address: [email protected].
  • 3 School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Electronic address: [email protected].
PMID: 40097133 DOI: 10.1016/j.ejphar.2025.177513
Abstract

Atherosclerosis is induced by lipid accumulation, inflammation, and endothelial dysfunction, and is the leading cause of death from Cardiovascular Disease worldwide. The P2Y6 receptor can be activated by the extracellular release of UDP. The evidence from the last decade has highlighted its critical therapeutic effect in atherosclerosis, yet with unclear mechanisms. This review introduced the P2Y6 receptor in atherosclerosis, and its mechanisms of atherosclerosis-promoting in macrophages, endothelial cells, and vascular smooth muscle cells. Finally, we discussed the development and potential of P2Y6 receptor antagonists in treating atherosclerosis.

Keywords

Atherosclerosis; Foam cell; Inflammation; Lipid accumulation; P2Y(6) receptor.

Figures